These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 16359438)

  • 41. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
    Koutsilieris M; Mitsiades CS; Bogdanos J; Dimopoulos T; Karamanolakis D; Milathianakis C; Tsintavis A
    Clin Cancer Res; 2004 Jul; 10(13):4398-405. PubMed ID: 15240528
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Therapeutic options for hormone-refractory prostate cancer in 2007.
    Hadaschik BA; Gleave ME
    Urol Oncol; 2007; 25(5):413-9. PubMed ID: 17826663
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment of androgen-independent, hormone-refractory prostate cancer with docetaxel in Japanese patients.
    Miyoshi Y; Uemura H; Nakamura M; Hasumi H; Sugiura S; Makiyama K; Nakaigawa N; Kishida T; Ogawa T; Yao M; Kubota Y
    Int J Clin Oncol; 2005 Jun; 10(3):182-6. PubMed ID: 15990966
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A weekly schedule of docetaxel for metastatic hormone-refractory prostate cancer.
    Ferrero JM; Foa C; Thezenas S; Ronchin P; Peyrade F; Valenza B; Lesbats G; Garnier G; Boublil JL; Tchiknavorian X; Chevallier D; Amiel J
    Oncology; 2004; 66(4):281-7. PubMed ID: 15218295
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: preliminary results of cancer and leukemia group B Trial 9780.
    Savarese D; Taplin ME; Halabi S; Hars V; Kreis W; Vogelzang N
    Semin Oncol; 1999 Oct; 26(5 Suppl 17):39-44. PubMed ID: 10604268
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Docetaxel (Taxotere)-based chemotherapy for hormone-refractory and locally advanced prostate cancer.
    Oh WK; Kantoff PW
    Semin Oncol; 1999 Oct; 26(5 Suppl 17):49-54. PubMed ID: 10604270
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy.
    Zhang HL; Yang LF; Zhu Y; Yao XD; Zhang SL; Dai B; Zhu YP; Shen YJ; Shi GH; Ye DW
    Prostate; 2011 Feb; 71(3):326-31. PubMed ID: 20842666
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Docetaxel for the treatment of prostate cancer.
    Gilbert DC; Parker C
    Future Oncol; 2005 Jun; 1(3):307-14. PubMed ID: 16556003
    [TBL] [Abstract][Full Text] [Related]  

  • 49. What next after hormonotherapy in cancer prostate?
    Parvez T; Al-sisi H; Ibraheim I
    J Coll Physicians Surg Pak; 2003 Oct; 13(10):606-10. PubMed ID: 14588180
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Changing perspectives of the role of chemotherapy in advanced prostate cancer.
    Burgess EF; Roth BJ
    Urol Clin North Am; 2006 May; 33(2):227-36, vii. PubMed ID: 16631461
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Chemotherapy for prostate cancer].
    Itoh N
    Nihon Rinsho; 2005 Feb; 63(2):293-7. PubMed ID: 15714981
    [TBL] [Abstract][Full Text] [Related]  

  • 52. New approaches in hormone refractory prostate cancer.
    Sonpavde G; Hutson TE
    Am J Clin Oncol; 2006 Apr; 29(2):196-201. PubMed ID: 16601442
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Current chemotherapeutic approaches for androgen-independent prostate cancer.
    Rumohr JA; Chang SS
    Curr Opin Investig Drugs; 2006 Jun; 7(6):529-33. PubMed ID: 16784023
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Docetaxel and prostate cancer].
    Ferrero JM
    Bull Cancer; 2004 Feb; 91(2):172-7. PubMed ID: 15047457
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hormone refractory prostate cancer: Management and advances.
    Sonpavde G; Hutson TE; Berry WR
    Cancer Treat Rev; 2006 Apr; 32(2):90-100. PubMed ID: 16458434
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Docetaxel (taxotere) in the treatment of prostate cancer.
    Beer TM; El-Geneidi M; Eilers KM
    Expert Rev Anticancer Ther; 2003 Jun; 3(3):261-8. PubMed ID: 12820771
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The evolving role of docetaxel in the management of androgen independent prostate cancer.
    Khan MA; Carducci M; Partin AW
    J Urol; 2003 Nov; 170(5):1709-16. PubMed ID: 14532760
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Docetaxel-based regimens, the standard of care for metastatic androgen-insensitive prostate cancer.
    Arlen PM; Gulley JL
    Future Oncol; 2005 Feb; 1(1):19-22. PubMed ID: 16555972
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Present status and perspectives in the treatment of hormone-refractory prostate cancer.
    Silvestris N; Leone B; Numico G; Lorusso V; De Lena M
    Oncology; 2005; 69(4):273-82. PubMed ID: 16282706
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Update in the management of patients with hormone-refractory prostate cancer.
    Moore CN; George DJ
    Curr Opin Urol; 2005 May; 15(3):157-62. PubMed ID: 15815191
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.